The great advances in the field of theranostics has led to remarkable progress in the management of patients with prostate cancer with the use of 68Ga-PSMA-617/177Lu-PSMA-617, or with neuroendocrine tumors with the use of 68Ga/177Lu-DOTA-TATE, while showing limited side effects [69,70,71]. This evidence concerns the gene FOLH1 and prostate carcinoma.